Ionis Pharmaceuticals (IONS) vs MBX Biosciences (MBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 245.2% versus a loss of 35.9%. Ionis Pharmaceuticals is the larger company by market cap ($7.24 billion vs $2.50 billion), about 2.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | MBX |
|---|---|---|
| Share price | $43.57 | $51.86 |
| Market cap | $7.24B | $2.50B |
| 1-day change | -1.35% | -4.91% |
| YTD return | -44.18% | +72.92% |
| 1-year return | -35.94% | +245.19% |
| 5-year return | +25.81% | — |
| EPS (TTM) | $-3.48 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | — |
| Revenue growth (YoY) | +33.83% | — |
| Net income (latest FY) | $-381.39M | $-87.00M |
| Gross margin | 98.31% | — |
| Operating margin | -40.45% | — |
| Net margin | -40.41% | — |
| 52-week high | $86.74 | $72.64 |
| 52-week low | $42.63 | $12.94 |
| Distance from 52-week high | -49.78% | -28.61% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +91.99% | +81.84% |
| Average volume | 3.78M | 539.34K |
| Shares outstanding | 166.18M | 48.16M |
| Employees | 1,480 | 63 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Ionis Pharmaceuticals is about 2.9 times larger than MBX Biosciences by market value ($7.24B vs $2.50B).
- MBX has outperformed IONS by 281.1 percentage points over the past year.
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
IONS vs MBX FAQ
Which is bigger, Ionis Pharmaceuticals or MBX Biosciences?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $7.24B compared with $2.50B for MBX Biosciences (MBX).
Which stock has performed better over the past year, IONS or MBX?
MBX returned +245.19% over the past 12 months, compared with -35.94% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and MBX Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.